- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Generic latanoprost now available
A generic version of latanoprost ophthalmic solution 0.005% is now available following the FDA's final approval of Mylan Pharmaceutical's abbreviated new drug application for a former proprietary solution (Xalatan, Pfizer) to lower IOP in patients with ocular hypertension or glaucoma.
Pittsburgh-A generic version of latanoprost ophthalmic solution 0.005% is now available following the FDA’s final approval of Mylan Pharmaceutical’s abbreviated new drug application for a former proprietary solution (Xalatan, Pfizer) to lower IOP in patients with ocular hypertension or glaucoma.
“We are very pleased to introduce this product to the market, as it represents Mylan’s first ophthalmic solution,” said Heather Bresch, president of parent company Mylan Inc. “This signifies a new internal development capability for the company, and we currently have in development a number of additional products in this important category.”
The prostaglandin analog had U.S. sales of about $711 million for the 12-month period ending Dec. 31, according to health-care industry information services company IMS Health.
